NCT06012916View on ClinicalTrials.gov

Brain Network Dynamics of Depression During Esketamine Treatment

CompletedOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

July 3, 2023

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions
Depressive Disorder, Major
Interventions
DRUG

Esketamine nasal spray

This is an observational study. The Esketamine nasal spray is administered by the attending physician during a regular treatment appointment at the Interventional Psychiatry Clinic. Esketamine dosages may range between 28-84mg. The study does not interfere with the individual treatment plan in any way.

Trial Locations (1)

27516

Carolina Center for Neurostimulation, Chapel Hill

All Listed Sponsors
lead

University of North Carolina, Chapel Hill

OTHER